
Suicide Risk From Weight-Loss Drugs Prompts More EU Questions
The European Union’s drugs regulator has asked pharma companies including Novo Nordisk A/S and Eli Lilly & Co.
1970-01-01 08:00

Altimmune Jumps 66% After Positive Results for Its Obesity Drug
Altimmune Inc. jumped as much as 66% in late trading after the biotech company reported results from a
1970-01-01 08:00

Forget Novo, Rolls-Royce Is Europe’s Best Stock This Year
Rolls-Royce Holdings Plc just extended its status as Europe’s best performing stock this year. The shares rose as
1970-01-01 08:00

Long-Time Novo Bull Slashes Stake Citing Weight-Loss Drug Hype
A top-performing European fund manager is calling time on “hype” around weight-loss drugs that has sent Novo Nordisk
1970-01-01 08:00

Ozempic Maker Novo Nordisk Invests $2.3 Billion in France Site
Novo Nordisk A/S, which faces supply bottlenecks amid high demand for its blockbuster weight-loss medicines, will invest €2.1
1970-01-01 08:00

New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype
A niche issuer is launching a biotechnology exchange-traded fund whose key holdings include firms benefiting from the hype
1970-01-01 08:00

Novo Nordisk Staff Get Free Wegovy As a Perk If They Need It
If you’re a Novo Nordisk A/S employee with obesity, you will have access to a unique company perk:
1970-01-01 08:00

Germany Mulls Obesity Drug Export Ban as EU Confronts Shortage
Germany is considering an export ban on Novo Nordisk A/S’s blockbuster weight-loss drugs as European countries try to
1970-01-01 08:00

Novo Shares Rise After Wegovy Demonstrates Heart Benefit in Trial
Novo Nordisk A/S shares surged after a key study backed the use of Wegovy, its blockbuster weight-loss drug,
1970-01-01 08:00

Trump’s Bet in Iowa, Wegovy Study: Your Saturday US Briefing
Good morning from Washington, where Congress is up against a Nov. 17 deadline when government funding runs out.Donald
1970-01-01 08:00

Wegovy Study Bolsters Use In Patients With Obesity and Heart Disease
Novo Nordisk A/S unveiled details from a closely watched study that support use of Wegovy, its blockbuster weight-loss
1970-01-01 08:00

Weight-Loss Drugs Among the Most Sought-After New Corporate Benefits
The craze around pricey weight-loss drugs has many people clamoring for these treatments in company-sponsored health plans. While
1970-01-01 08:00